These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25880488)

  • 21. Virologic and immunologic studies of human prostatic carcinoma.
    Dmochowski L; Maruyama K; Ohtsuki Y; Seman G; Bowen JM; Newton WA; Johnson DE
    Cancer Chemother Rep; 1975; 59(1):17-31. PubMed ID: 48414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benign prostatic hyperplasia and prostate carcinoma in native Africans.
    Dawam D; Rafindadi AH; Kalayi GD
    BJU Int; 2000 Jun; 85(9):1074-7. PubMed ID: 10848698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.
    Li MK; Garcia L; Patron N; Moh LC; Sundram M; Leungwattanakij S; Pripatnanont C; Cheng C; Chi-Wai M; Loi-Cheong N
    BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia.
    Chirikos TN; Sanford E
    J Urol; 1996 Apr; 155(4):1311-6. PubMed ID: 8632563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of health care costs and co-morbidities between men diagnosed with benign prostatic hyperplasia and cardiovascular disease (CVD) and men with CVD alone in a US commercial population.
    Shah M; Butler M; Bramley T; Curtice TG; Fine S
    Curr Med Res Opin; 2007 Feb; 23(2):417-26. PubMed ID: 17288695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The economics of benign prostatic hyperplasia treatment: a literature review.
    Kortt MA; Bootman JL
    Clin Ther; 1996; 18(6):1227-41. PubMed ID: 9001839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A nationwide survey of practicing urologists: current management of benign prostatic hyperplasia and clinically localized prostate cancer.
    Barry MJ; Fowler FJ; Bin L; Oesterling JE
    J Urol; 1997 Aug; 158(2):488-91; discussion 492. PubMed ID: 9224330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a decision aid for the treatment of benign prostatic hyperplasia: A four stage method using a Delphi consensus study.
    Lamers RED; Cuypers M; Garvelink MM; de Vries M; Bosch JLHR; Kil PJM
    Patient Educ Couns; 2016 Jul; 99(7):1249-1256. PubMed ID: 26899631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK.
    Speakman M; Kirby R; Doyle S; Ioannou C
    BJU Int; 2015 Apr; 115(4):508-19. PubMed ID: 24656222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of symptomatic BPH in France: who is treated and how?
    Lukacs B
    Eur Urol; 1999; 36 Suppl 3():14-20. PubMed ID: 10559626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Annual costs of benign prostatic hyperplasia in New Zealand.
    Scott WG; Scott HM
    Pharmacoeconomics; 1993 Dec; 4(6):455-68. PubMed ID: 10151048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benign Prostatic Hyperplasia and the Risk of Prostate Cancer and Bladder Cancer: A Meta-Analysis of Observational Studies.
    Dai X; Fang X; Ma Y; Xianyu J
    Medicine (Baltimore); 2016 May; 95(18):e3493. PubMed ID: 27149447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
    Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
    Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of histological prostatitis in men with benign prostatic hyperplasia or adenocarcinoma of the prostate presenting without urinary retention.
    Edlin RS; Heyns CF; Van Vuuren SP; Zarrabi AD
    S Afr J Surg; 2012 Nov; 50(4):127-30. PubMed ID: 23217554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New insights into the epidemiology and natural history of benign prostatic hyperplasia.
    Boyle P
    Prog Clin Biol Res; 1994; 386():3-18. PubMed ID: 7528398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phytotherapy for benign prostatic hyperplasia.
    Wilt TJ; Ishani A; Rutks I; MacDonald R
    Public Health Nutr; 2000 Dec; 3(4A):459-72. PubMed ID: 11276294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The ability of systematic transrectal ultrasound guided biopsy to detect prostate cancer in men with the clinical diagnosis of benign prostatic hyperplasia.
    Coplen DE; Andriole GL; Yuan JJ; Catalona WJ
    J Urol; 1991 Jul; 146(1):75-7. PubMed ID: 1711588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benign prostatic hyperplasia and prostate cancer: an overview for primary care physicians.
    Sausville J; Naslund M
    Int J Clin Pract; 2010 Dec; 64(13):1740-5. PubMed ID: 21070524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The long-term cost effectiveness of treatments for benign prostatic hyperplasia.
    DiSantostefano RL; Biddle AK; Lavelle JP
    Pharmacoeconomics; 2006; 24(2):171-91. PubMed ID: 16460137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.